The effectiveness of HPV vaccine and the breakthrough cases

2024 Fiscal Year Final Research Report

• Project/Area Number: 20K09677
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56040:Obstetrics and gynecology-related
• Research Institution: Showa University
• Principal Investigator: Mamiko Onuki 昭和大学, 医学部, 准教授 (20573744)
• Co-Investigator(Kenkyū-buntansha): 松本 光司 昭和大学, 医学部, 教授 (30302714) ; 柊元 巌 国立感染症研究所, 病原体ゲノム解析研究センター, 室長 (70291127)
• Project Period (FY): 2020-04-01 – 2025-03-31
• Keywords: HPVワクチン / 子宮頸癌 / 子宮頸部上皮内腫瘍

Outline of Final Research Achievements

Cases of HPV16/18-positive cervical cancer and precancerous lesions after HPV vaccination in Japanese women under 40 years of age registered in “Study for Monitoring project for the Impact of National HPV vaccinaTion program in Japan” were defined in the broad sense. Breakthrough cases were defined as cases in which HPV16/18-positive cervical cancer or precancerous lesions developed after HPV vaccination. We examined the relationship between the age of first sexual intercourse and the age of vaccination in these cases, and examined the proportion of cases who were already infected at the time of vaccination. More than 100 breakthrough cases in the broad sense were enrolled during the study period. In the population for which the relationship between age of vaccination and age of first intercourse was known, all cases were vaccinated later than the age of first intercourse and could be assumed to have been previously infected at the time of vaccination.

Free Research Field

婦人科腫瘍学

Academic Significance and Societal Importance of the Research Achievements

HPVワクチン接種後かつHPV16/18陽性の子宮頸部病変患者を対象に接種年齢、初交年齢など詳細に解析した。ワクチンの恩恵を最大に受けるためには接種時期が重要であることを日本人女性のデータとして学会発表や論文により公表できたと考えている。また本邦での定期接種年齢の上限が16歳であることが、世界と比較しても遅い上に、本邦でも16歳接種ではワクチン効果が一部不十分となる集団がいることをデータとして示し、定期接種年齢上限の引き下げについても学会や講演会などで提言を行った。